Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 8/20 | 0.54 |
| ▸ | CA2 | P00918 | 8/20 | 0.54 |
| ▸ | CA12 | O43570 | 6/20 | 0.54 |
| ▸ | CA9 | Q16790 | 6/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.53 |
| ▸ | STK17B | O94768 | 1/20 | 0.48 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14242963 | 0.96 | TDP1 (0.72) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL20104760 | 0.94 | TDP1 (0.76) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL569251 | 0.94 | TDP1 (0.74) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL15427310 | 0.91 | TDP1 (0.60) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL3020258 | 0.89 | TDP1 (0.81) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL1557057 | 0.88 | TDP1 (0.67) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL134329 | 0.87 | TDP1 (0.85) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL3025184 | 0.87 | TDP1 (0.85) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL137629 | 0.87 | TDP1 (0.85) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL5162656 | 0.87 | TDP1 (0.85) | TDP1MEN1GAAKMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223306-A1 | TEAD INHIBITORS AND METHODS OF USE | SPOROS BIOVENTURES, INC., | 2025-07-10 | — | — | US | disclosed |
| EP-4496789-A1 | TEAD INHIBITORS AND METHODS OF USE | Sporos Biodiscovery, Inc. (US) | 2025-01-29 | — | — | EP | disclosed |
| WO-2023183437-A1 | TEAD INHIBITORS AND METHODS OF USE | SPOROS BIODISCOVERY, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183437-A1 | TEAD INHIBITORS AND METHODS OF USE | SPOROS BIODISCOVERY, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-1323708-B1 | Method for producing carbamates and method for producing isocyanates | MITSUI TAKEDA CHEMICALS INC (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223306-A1 | TEAD INHIBITORS AND METHODS OF USE | TEAD1, TEAD2, TEAD3 | TDP1 619/4885MEN1 4168/4885GAA 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.